Latest news with #TSXVenture
Yahoo
23-05-2025
- Business
- Yahoo
DIAGNOS Announces the Engagement of Allele Capital Partners
BROSSARD, Quebec, May 23, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. ('DIAGNOS' or the 'Corporation') (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence (AI), announces the engagement of Allele Capital Partners, LLC ('Allele') to provide capital markets advisory and social media services to the Corporation. As per the agreement signed between Allele and DIAGNOS, Allele is entitled to a monthly compensation of US$7,500, payable in advance in cash, for the period of May 22, 2025 to August 22, 2025 (the 'Trial Period'). During the Trial Period, DIAGNOS may terminate the agreement at its sole discretion with thirty (30) business days advanced written notice to Allele. Upon expiry of the Trial Period, the agreement shall renew, upon written confirmation from DIAGNOS, for an additional nine (9) months at the same monthly compensation fee of US$7,500. At its sole discretion, Allele may terminate the agreement at any time during the term. The compensation will be paid using the liquidities of the Corporation. Headquartered in Southeast Florida, USA, Allele provides capital markets advisory and merchant banking services to life science companies. As part of the services to be rendered to the Corporation, Allele will assist DIAGNOS in refining and strengthening its business strategy in order to optimize milestones, capital needs and capital markets objectives with the ultimate goal of maximizing shareholder value. Allele is acting at arm's length to the Corporation. As of the date of this announcement, Allele, together with any of its principals, do not have any interest, directly or indirectly, in the securities of the Corporation. The engagement of Allele is subject to the acceptance of the TSX Venture Exchange. About DIAGNOSDIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical eye-related health problems. By leveraging Artificial Intelligence, DIAGNOS aims to provide more information to healthcare clinicians to enhance diagnostic accuracy, streamline workflows, and improve patient outcomes on a global scale. Additional information is available at and This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. CONTACT: For further information, please contact: Mr. André Larente, President DIAGNOS Inc. Tel: 450-678-8882 ext. 224 alarente@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
23-05-2025
- Business
- Yahoo
Abcourt Announces its Results for the Third Quarter Ended March 31, 2025
ROUYN-NORANDA, Quebec, May 22, 2025 (GLOBE NEWSWIRE) -- Abcourt Mines Inc. ('Abcourt' or the 'Corporation') (TSX Venture: ABI) (OTCQB : ABMBF) announces its results for the third quarter ended March 31, 2025. All monetary values in this press release are expressed in Canadian dollars, unless otherwise indicated. Financial statements and management discussion and analysis are available on SEDAR+. Summary of financial results (In dollars) Three months endedMarch 31 Nine months endedMarch 31 2025 2024 2025 2024 Revenues – – – 255,000 Administration expenses 1,068,917 776,367 2,499,582 2,657,981 Care and maintenance 692,919 231,541 2,743,950 2,031,082 Exploration expenses 4,063,635 1,765,615 6,118,177 4,043,679 Settlement of litigation with Revenu Québec – – (1,452,757 ) – Deferred income and mining taxes (1,100,000 ) – (1,273,000 ) (170,712 ) Net loss and comprehensive loss (5,466,608 ) (2,892,142 ) (9,756,976 ) (8,692,837 ) Net loss per share, basic and diluted (0.01 ) (0.01 ) (0.01 ) (0.02 )(In dollars) March 31, 2025 June 30, 2024 Cash 937,733 757,753 Total assets 16,493,159 14,063,983 Non-current liabilities 12,908,748 12,261,315 Shareholders' equity (3,447,876 ) (6,284,136 ) Working capital (non-IFRS measurement) * (2,172,892 ) (4,947,411 ) * Working capital is a non-IFRS measurement with no standardized meaning under IFRS. For further information, please see section "Non-IFRS Measure". Abcourt has achieved a significant improvement in its working capital for the period ended March 31, 2025, with a negative working capital of $2,172,892, compared to negative working capital of $4,947,411 as at June 30, 2024. Non-IFRS Measure This press release presents working capital as a performance measure which is non-International Financial Reporting Standards (IFRS) performance measure. The Corporation believes that this measure provides investors with an improved ability to evaluate the performance of the Corporation. Non-IFRS measures do not have any standardized meaning prescribed under IFRS. Therefore, such measures may not be comparable to similar measures employed by other companies. This data may not be comparable to data presented by other companies. Non-GAAP financial performance measures should be considered together with other data prepared in accordance with IFRS. The Corporation determines working capital as follows: current assets less current liabilities. Abcourt Mines Inc. Abcourt Mines Inc. is a Canadian gold exploration company with properties strategically located in northwestern Quebec, Canada. Abcourt owns the 100% owned Sleeping Giant mine and mill and the Flordin exploration property, where it focuses its operations. For more information about Abcourt Mines Inc., please visit our website and view our filings under Abcourt's profile on Pascal Hamelin Dany Cenac Robert, Investor Relations President and Chief Executive Officer Reseau ProMarket Inc., T : (819) 768-2857 T : (514) 722-2276, poste 456 Email : phamelin@ Email : FORWARD-LOOKING STATEMENTS Certain information contained in this news release may constitute "forward-looking information" within the meaning of Canadian securities legislation. Generally, forward-looking information can be identified by using forward-looking terminology, such as "plans", "aims", "expects", "projects", "intends", "anticipates", "estimates", "could", "should", "likely", or variations of such words and phrases or statements specifying that certain acts, events or results "may", "should", "will" or "be achieved" or other similar expressions. Forward-looking statements are based on Abcourt's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause Abcourt's actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking statements or information. Forward-looking statements are subject to business, economic and uncertainties and other factors that could cause actual results to differ materially from these forward-looking statements, including the relevant assumptions and risk factors set forth in Abcourt's public filings, which are available on SEDAR at There can be no assurance that these statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Although Abcourt believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on such statements. Except as required by applicable securities laws, Abcourt disclaims any intention or obligation to update or revise any such forward-looking statements or information, whether as a result of new information, future events or otherwise. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release
The Market Online
12-05-2025
- Business
- The Market Online
Profitable all-in-food tech co. plots M&A growth strategy
Eshbal Functional Food Inc has recently listed on the TSXV and the company with profitable operations in Israel is now looking to expand into the fast growing, gluten-free North American market with an ambitious M&A strategy. LYNDSAY: My first question is there, you have said actually many times, there is no one like us, so I'd love to hear more about that and what makes Eshbal so different? TOMER: Perfect. I'll tell you what I think it is. First of all, we're an all-in-food tech company, and have been doing this for many years, everything from production, development is done in-house, which gives us full control and ensures we keep the highest standards for our products. Second, our focus is on Better For You Foods with a strong emphasis on gluten-free solutions. We work to make products that taste and feel like the real thing, but without compromising on nutritional value or taste, which are very important. Third, we know from experience that we're not just making food, we're actually helping people with real dietary needs and that's why you focus on creating solutions, not just products. And last, I would say unlike most food or biotech companies on the TSX Venture, which are often still pre-revenue or very early stage, Eshbal already has significant commercial activity with nearly $12 million, US dollars which are about 16 million Canadian dollars in revenues. And that makes us one of the few companies on the exchange with real sales, real operations and a strong foundation for growth. LYNDSAY: Well, you've given so many positive facts, so why go the M&A route? What are the advantages? TOMER: For us, M&A is a way to grow faster and smarter. Instead of building everything from scratch, we look to acquire companies with strong products, production, distribution, or market connections giving us a shorter time to market in quicker scale and is how we grew the business so far, and it's how we plan to keep on growing. In fact, I joined Eshbal through a successful acquisition back in 2016. We believe we know how to find the right fit and create value quickly. LYNDSAY: Maybe you can then walk me through the kinds of companies you're targeting and what makes them so appealing. TOMER: We're actually targeting two main types of companies. The first one is what we call brand companies. These are companies with existing sales market reach or distribution networks, companies that already have a customer relationship and know how to move product in North America, which is really important. The second type, we call operational companies. These are mainly manufacturers with proven capabilities, especially in gluten-free or better for you foods. This will help us create a footprint in the market, and the appeal is that we don't have to reinvent the wheel. We can plug into what already works, bring in our products and scale together, find businesses that create synergy where one in one equals three, that will help us promote our business quicker. LYNDSAY: We know that you are in Israel and we also know that running a business in North America is a lot different than Israel. So how are you getting ready to navigate those cultural differences? TOMER: There's definitely a cultural difference, things like communication style, decision making, and how relationships are built. That's why one of the first thing we already started is building a local team in North America who understands the business, business culture, and can help us bridge that gap. On the product side, however, especially in gluten-free, we actually see a lot of similarities. The needs are very close and we actually see a strong fit. LYNDSAY: What should we be watching for with Bel in the next quarters? TOMER: In the coming months, we're moving into commercial production in North America. We've already run successful tryouts with local co-producers, and we're now preparing to launch our gluten-free products through them. At the same time, we're starting to roll out our marketing strategy to introduce the product to the market. And the most exciting part on the M&A side, we're in active discussions with several potential targets and our goal is to complete at least one within the next few months. You can find Eshbal on the venture exchange trading under the ticker symbol, ESBL, and their website is Join the discussion: Find out what everybody's saying about this stock on the Eshbal Functional Food investor discussion forum, and check out the rest of Stockhouse's stock forums and message boards. The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here
Associated Press
28-04-2025
- Business
- Associated Press
Signs Strategic Licensing Agreement
KELOWNA, BC / ACCESS Newswire / April 28, 2025 / TOTAL TELCOM INC. (TSX Venture:TTZ) announced today its wholly owned subsidiary ROM Communications Inc has entered into a strategic agreement to sell the intellectual property of two proprietary heater controllers to a private company for a lump sum of $100,000.00 plus a royalty of $35 for each controller manufactured over the next 15 years. The buyer has an established presence in heater markets, including significant customer relationships and distribution channels. Target market segments for these controllers are to include trucking, forestry, construction, service vehicles, school buses, and commercial and pleasure vessels. ROM will continue to provide technical expertise and support for new applications, ensuring the products' adaptability and performance across multiple market segments. Company CEO, Neil Magrath stated, 'the agreement allows ROM to focus on innovation and technical support, while generating royalty-based revenue without the operational expenses of manufacturing, inventories & marketing. This initiative aligns with ROM's growth strategy of forming strategic partnerships to expand the reach of its products and services. Based on the success of this model, the company also intends to explore similar partnership opportunities in the future.' Trading symbol: TTZ: TSX Venture For further information regarding this press release please contact Neil Magrath, CEO at (250) 860-3762 (Ext 202) Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE: Total Telcom Inc. press release
Yahoo
06-03-2025
- Business
- Yahoo
BioSyent Schedules Fourth Quarter and Full Year 2024 Earnings Release for March 13, 2025
MISSISSAUGA, Ontario, March 06, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. ('BioSyent', 'the Company', TSX Venture: RX) will be reporting its financial results for the three months and full year ended December 31, 2024 on Thursday, March 13, 2025 after market hours. A presentation on the Company's fourth quarter and full year 2024 results by René Goehrum, BioSyent President and CEO, will also be available on the Company's website on the date of release. About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol 'RX', BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty and international business units. As of the date of this press release, the Company has 11,264,517 common shares outstanding. For a direct market quote for the TSX Venture Exchange and other Company financial information please visit For further information please contact: Mr. René C. GoehrumPresident and CEOBioSyent Inc.E-Mail: investors@ 905-206-0013Web: This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press in to access your portfolio
